دورية أكاديمية
أعرض في EDS

Is Inhaled Furosemide a Potential Therapeutic for COVID-19?

التفاصيل البيبلوغرافية
العنوان: Is Inhaled Furosemide a Potential Therapeutic for COVID-19?
المؤلفون: Brennecke A; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada., Villar L; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada., Wang Z; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada., Doyle LM; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada., Meek A; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada., Reed M; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada., Barden C; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada., Weaver DF; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Faculty of Medicine, University of Toronto, Medical Sciences Building, Toronto, Ontario, Canada. Electronic address: dweaver@uhnres.utoronto.ca.
المصدر: The American journal of the medical sciences [Am J Med Sci] 2020 Sep; Vol. 360 (3), pp. 216-221. Date of Electronic Publication: 2020 Jun 01.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 0370506 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-2990 (Electronic) Linking ISSN: 00029629 NLM ISO Abbreviation: Am J Med Sci Subsets: MEDLINE
أسماء مطبوعة: Publication: 2016- : New York : Elsevier
Original Publication: Philadelphia : J. B. Lippincott
مواضيع طبية MeSH: Betacoronavirus/*drug effects , Coronavirus Infections/*drug therapy , Furosemide/*administration & dosage , Immunity, Innate/*drug effects , Pneumonia, Viral/*drug therapy, Administration, Inhalation ; Antiviral Agents/administration & dosage ; Antiviral Agents/pharmacokinetics ; Betacoronavirus/immunology ; Betacoronavirus/metabolism ; COVID-19 ; Coronavirus Infections/immunology ; Coronavirus Infections/metabolism ; Furosemide/pharmacokinetics ; Humans ; Immunity, Innate/physiology ; Inflammation Mediators/antagonists & inhibitors ; Inflammation Mediators/immunology ; Inflammation Mediators/metabolism ; Pandemics ; Pneumonia, Viral/immunology ; Pneumonia, Viral/metabolism ; SARS-CoV-2 ; Sodium Potassium Chloride Symporter Inhibitors/administration & dosage ; Sodium Potassium Chloride Symporter Inhibitors/pharmacokinetics
مستخلص: The potentially lethal infection caused by the novel Severe Acute Respiratory Disease Coronavirus-2 (SARS-CoV-2) has evolved into a global crisis. Following the initial viral infection is the host inflammatory response that frequently results in excessive secretion of inflammatory cytokines (e.g., IL-6 and TNFα), developing into a self-targeting, toxic "cytokine storm" causing critical pulmonary tissue damage. The need for a therapeutic that is available immediately is growing daily but the de novo development of a vaccine may take years. Therefore, repurposing of approved drugs offers a promising approach to address this urgent need. Inhaled furosemide, a small molecule capable of inhibiting IL-6 and TNFα, may be an agent capable of treating the Coronavirus Disease 2019 cytokine storm in both resource-rich and developing countries. Furosemide is a "repurpose-able" small molecule therapeutics, that is safe, easily synthesized, handled, and stored, and is available in reasonable quantities worldwide.
(Copyright © 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.)
References: Lancet. 2020 May 9;395(10235):1517-1520. (PMID: 32311318)
Br J Dermatol. 2019 May;180(5):1058-1068. (PMID: 30580460)
Am J Respir Crit Care Med. 2000 Jun;161(6):1963-7. (PMID: 10852774)
Virology. 1996 May 1;219(1):291-4. (PMID: 8623543)
J Pain Symptom Manage. 2002 Sep;24(3):274-5; author reply 275-6. (PMID: 12458098)
Clin Pharmacol Ther. 1980 Jun;27(6):784-90. (PMID: 7379446)
Respir Res. 2011 Jan 18;12:11. (PMID: 21241520)
J Thorac Cardiovasc Surg. 2017 Jan;153(1):206-215. (PMID: 27986254)
Respir Res. 2018 Sep 20;19(1):181. (PMID: 30236110)
J Pharmacokinet Biopharm. 1979 Feb;7(1):1-27. (PMID: 458552)
J Gen Virol. 1993 Aug;74 ( Pt 8):1519-25. (PMID: 8393911)
Eur Respir J. 1992 Nov;5(10):1184-8. (PMID: 1486963)
Rheumatology (Oxford). 2017 Sep 1;56(9):1628-1629. (PMID: 28575416)
Int Immunopharmacol. 2013 Nov;17(3):721-6. (PMID: 24029595)
Ann Allergy Asthma Immunol. 1999 Dec;83(6 Pt 1):559-66. (PMID: 10619350)
Virology. 1989 Sep;172(1):42-50. (PMID: 2549721)
Am J Respir Crit Care Med. 1999 Jun;159(6):1843-8. (PMID: 10351929)
Arch Virol. 2006 Dec;151(12):2495-501. (PMID: 16932984)
J Hypertens. 2006 May;24(5):915-22. (PMID: 16612254)
Pediatr Pulmonol. 1994 Aug;18(2):93-8. (PMID: 7970925)
Respir Physiol Neurobiol. 2018 Jan;247:24-30. (PMID: 28843675)
Allergol Immunopathol (Madr). 2006 Mar-Apr;34(2):54-8. (PMID: 16606546)
Proc Soc Exp Biol Med. 1965 Feb;118:333-6. (PMID: 14268614)
Clin Infect Dis. 2020 Jul 28;71(15):762-768. (PMID: 32161940)
Respir Care. 2007 Jul;52(7):900-10. (PMID: 17594733)
Am J Ther. 2002 Jul-Aug;9(4):317-28. (PMID: 12115021)
Am Rev Respir Dis. 1991 Jun;143(6):1329-33. (PMID: 2048820)
Sci Rep. 2018 Jun 29;8(1):9877. (PMID: 29959396)
J Asthma. 1998;35(1):89-93. (PMID: 9513587)
Respir Physiol Neurobiol. 2007 Apr 16;156(1):1-8. (PMID: 16935035)
Lancet. 1988 Jul 30;2(8605):252-5. (PMID: 2899239)
Chest. 2008 Jun;133(6):1388-1396. (PMID: 18339790)
Front Physiol. 2018 Feb 12;9:86. (PMID: 29483879)
JAMA. 2020 Feb 25;323(8):707-708. (PMID: 31971553)
Chest. 1993 Jul;104(1):185-8. (PMID: 8325066)
West Afr J Med. 2005 Jul-Sep;24(3):246-51. (PMID: 16276705)
Proc Soc Exp Biol Med. 1966 Oct;123(1):17-22. (PMID: 5924423)
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331. (PMID: 32171193)
J Asthma. 1997;34(4):283-9. (PMID: 9250252)
JAMA Netw Open. 2020 Jun 1;3(6):e2011122. (PMID: 32525548)
Am Heart J. 1977 Jul;94(1):6-13. (PMID: 868744)
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. (PMID: 32350134)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Front Immunol. 2020 May 01;11:827. (PMID: 32425950)
N Engl J Med. 1998 Aug 6;339(6):387-95. (PMID: 9691107)
J Crit Care. 2020 Jun;57:279-283. (PMID: 32173110)
Am J Physiol. 1973 Jul;225(1):119-24. (PMID: 4714389)
Lancet Respir Med. 2020 May;8(5):475-481. (PMID: 32105632)
Ann Clin Biochem. 2020 May;57(3):262-265. (PMID: 32266828)
Biochem Pharmacol. 2018 Oct;156:60-67. (PMID: 30102895)
J Am Soc Nephrol. 1996 Feb;7(2):345-9. (PMID: 8785407)
Annu Rev Pharmacol Toxicol. 1976;16:201-14. (PMID: 779615)
فهرسة مساهمة: Keywords: COVID-19; Cytokine storm; Furosemide; IL-6; SARS-CoV-2
المشرفين على المادة: 0 (Antiviral Agents)
0 (Inflammation Mediators)
0 (Sodium Potassium Chloride Symporter Inhibitors)
7LXU5N7ZO5 (Furosemide)
تواريخ الأحداث: Date Created: 20200706 Date Completed: 20200901 Latest Revision: 20210129
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7833957
DOI: 10.1016/j.amjms.2020.05.044
PMID: 32622469
قاعدة البيانات: MEDLINE
الوصف
تدمد:1538-2990
DOI:10.1016/j.amjms.2020.05.044